These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25912107)

  • 21. Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent.
    Schneider VS; Skurk C; Riedel M; Abdelwahed YS; Landmesser U; Leistner DM
    Clin Res Cardiol; 2017 Jul; 106(7):557-559. PubMed ID: 28374059
    [No Abstract]   [Full Text] [Related]  

  • 22. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
    Džavík V; Colombo A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
    La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year outcomes of bioresorbable vascular scaffold versus drug-eluting stents in coronary artery disease: a meta-analysis.
    Nairooz R; Saad M; Sardar P; Aronow WS
    Heart; 2017 Jul; 103(14):1096-1103. PubMed ID: 28115471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry.
    Kraak RP; Hassell ME; Grundeken MJ; Koch KT; Henriques JP; Piek JJ; Baan J; Vis MM; Arkenbout EK; Tijssen JG; de Winter RJ; Wykrzykowska JJ
    EuroIntervention; 2015 Feb; 10(10):1160-8. PubMed ID: 25136885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction.
    Miyazaki T; Panoulas VF; Sato K; Naganuma T; Latib A; Colombo A
    Int J Cardiol; 2014 Jun; 174(2):e72-4. PubMed ID: 24784914
    [No Abstract]   [Full Text] [Related]  

  • 32. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients.
    Tröbs M; Achenbach S; Röther J; Klinghammer L; Schlundt C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):872-880. PubMed ID: 27142643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Polymeric Bioresorbable Vascular Scaffold Versus an Everolimus-Eluting Stent in ST-Segment Elevation Myocardial Infarction.
    Wernly B; Latib A; Ielasi A; Jung C
    J Invasive Cardiol; 2019 Sep; 31(9):E271-E272. PubMed ID: 31478894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention.
    Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R
    EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
    Lipinski MJ; Escarcega RO; Baker NC; Benn HA; Gaglia MA; Torguson R; Waksman R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):12-24. PubMed ID: 26762906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus eluting bioresorbable vascular scaffolds; can we absorb the risk in complex PCI?
    Zahr F; Cigarroa JE
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):70-71. PubMed ID: 28707440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.